Page 1

IN bio IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights August 6 , 2026 • Advanced next - generation gamma delta ( yō ) T cell engager ( TCE ) platform demonstrating a novel mechanism for yō T cell expansion , deep target cell depletion , and favorable cytokine profile ; Initial in vivo data expected in the second half of 2026 • Presented updated data at ASCO 2026 demonstrating median overall survival ( mOS ) exceeding 19.5 months and still climbing , across all patients with newly diagnosed glioblastoma ( GBM ) treated with repeat - dosing of DeltEx ™ Drug Resistant Immunotherapy ( DRI ) • Published peer - reviewed clinical data from Phase 1 INB - 200 trial in The Journal of Clinical Oncology ( JCO ) demonstrating DeltEx ™ DRI more than doubled expected median progression - free survival ( mPFS ) in newly diagnosed GBM • Reported new translational Al proteomic and immunogenomic analyses demonstrating DeltEx DRI preserves immune function and positively remodels the GBM tumor microenvironment , providing additional evidence supporting its therapeutic efficacy potential NEW YORK , Aug. 06 , 2026 ( GLOBE NEWSWIRE ) -- IN8bio . Inc. ( Nasdaq : INAB ) , a clinical - stage biopharmaceutical company developing innovative gamma - delta ( yo ) T cell therapies and yō T cell engagers ( TCEs ) for cancer and autoimmune diseases , today reported financial results and business highlights for the second quarter ended June 30 , 2026 . " The second quarter marked an important period of scientific and clinical validation for yō T cell therapeutics and IN8bio . Our yō TCE platform is progressing , with INB - 619 advancing into initial animal models . We are pleased to remain on track for reporting initial in vivo data this year , " said William Ho , Chief Executive Officer and co - founder of IN8bio . " In addition , peer - reviewed and updated clinical data from our glioblastoma program continue to demonstrate a favorable safety profile and provide strong evidence that yō T cells are clinically active and can be delivered safely to potentially improve patient outcomes . We remain focused on disciplined execution , as we continue to seek a regulatory pathway for our glioblastoma program , with the ultimate goal of bringing much needed treatment to patients . " Advancing Next - Generation yō TCE Platform ( INB - 619 ) • Continued advancement of proprietary INB - 600 platform of novel yō T cell engagers , designed to selectively eliminate targets such as CD19 , potentially reducing toxicities including cytokine release syndrome ( CRS ) and infections , while expanding the therapeutic window compared with conventional CD3 - targeting T cell engagers . • Advancing INB - 619 , a CD19 - targeting yo T cell engager for oncology and autoimmune diseases , into IND - enabling studies following encouraging early preclinical data demonstrating complete B cell depletion , robust yd T cell expansion , and minimal CRS - associated cytokine release , including IL - 6 and TNF - α . • Remain on track to report initial in vivo preclinical data in the second half of 2026 . Reported Clinical and Translational Advances for DeltEx ™ DRI in Newly Diagnosed Glioblastoma During the second quarter , IN8bio reported multiple clinical and scientific milestones supporting the clinical activity of yo T cells and IN8bio's DeltEx ™ DRI platform : • Published the first peer - reviewed clinical results of DeltEx DRI in newly diagnosed GBM in The Journal of Clinical Oncology . Among all patients treated , no dose - limiting toxicities ( DLTs ) , CRS or immune effector cell - associated neurotoxicity syndrome ( ICANS ) were observed . • Presented updated clinical data at the 2026 American Society of Clinical Oncology ( ASCO ) Annual Meeting demonstrating encouraging survival benefit in repeat - dose treated patients , with mPFS of 13.0 months versus 6.6 months for contemporaneously enrolled patients receiving only standard - of - care ( SOC ) and mOS exceeding 19.5+ months versus 13.2 months for SOC . • Approximately 43 % of repeat - dose patients remained alive at 24 months compared with 20 % of SOC patients . • Presented new translational data at the International Society for Cell & Gene Therapy ( ISCT ) and International Society for Cell & Gene Therapy ( ISCT ) and American Society of Gene & Cell Therapy ( ASGCT ) Annual Meetings integrating artificial intelligence ( AI ) , immunogenomics , histopathology , transcriptomics and spatial proteomics . Repeated DeltEx ™ DRI dosing demonstrated preserved immune function during chemotherapy and positively remodeled the glioblastoma tumor microenvironment .